Despite the fact that extracorporal photochemotherapy (ECP) is now broadly used for the treatment of graft versus host disease or T-cell lymphomas, the mechanisms of its action remain enigmatic. This work provides a synthesis of the main results suggesting the initiation by ECP of an immune reaction responsible for the down modulation of pathogenic T-cell functions, with a special focus on the role of dendritic cells in this phenomenon.
Extracorporeal photochemotherapy (ECP) is a cell therapy approved by FDA for the treatment of cutaneous T-cell lymphoma (CTCL). Since the evidence of its safety and clinical efficacy in the management of T-cell tumor manifestations, 1 ECP has been used in other human pathologic situations where an involvement of circulating pathogenic T cells is suspected, such as autoimmune diseases and rejection in organ transplantation and graft-versus-host disease (GVHD). In a recent review, 2 by analyzing data from 204 patients (20 series), Dall'Amico reported the clinical efficacy of ECP in association with an immunosuppressive regimen in the treatment of chronic GVHD. A clinical efficacy is achieved in 76% of patients with cutaneous, 48% with liver, and 39% with lung involvement. ECP is also an effective adjunct therapy for acute GVHD.
If the ECP procedure is rather simple, the mechanisms of action are more complex and remain enigmatic. The ECP process consists in the withdrawal by apheresis, of peripheral blood mononuclear cells (MNC) of the patient, the ex vivo incubation of MNC with the photoactivable drug 8-methoxypsoralen (8-MOP), followed by UV-A irradiation, and, finally, the infusion of photoinactivated cells to the patient. Between 10 and 15 billions of MNC containing the pathogenic T cells are treated in one ECP procedure. All along their treatment, patients receive about 5-50 or more procedures depending on the studies.
The main direct effects of ECP on treated circulating T cells are the consequence of the covalent interactions between DNA and 8-MOP under the UV-A light. Treated cells become unable to proliferate in vitro, and undergo apoptosis after several hours. 3, 4 If these effects are well characterized and affect all cells, they cannot explain, however, the efficacy of ECP by themselves, because only a small proportion of pathogenic T cells is treated during an ECP process. Indeed, in the GVHD, like in CTCL, the majority of pathogenic T cells are supposed to be located in the peripheral tissues or organs, and so are not directly affected by the 8-MOP/UV-A exposition. Moreover, at the moment of infusion of photoinactivated cells within 1 or 2 h following treatment, cells would not have undergone the apoptosis process. Until now, no data have confirmed the reality and the kinetics of in vivo treated cell death, and neither the consequences of this apoptosis on the biologic consequences for nontreated pathogenic T cells. It has been proposed that the immune system could be involved by downmodulating the pathogenic T-lymphocyte reactivity. Experimentally, photoinactivation of splenocytes with psoralen and UV-A light suppresses the induction of GVHD in mice 4, 5 but there are no data on the treatment of GVHD as such. Others studies have shown that infusions of photoinactivated antidonor T cells resulted in a prolonged retention of skin or organ allogeneic grafts, 6, 7 suggesting the development of an immune reaction responsible for the downmodulation of allogeneic reactive T-cell function. In vivo production of immunosuppressive cytokines by macrophages or monocytes, following ingestion of apoptotic cells, has been suggested as a general immune effect of ECP. A recent work has shown that irradiated MNC from patients with GVHD leads to a high synthesis of IL-10 and IL-1R antagonist mRNA by nontreated PBMC, after activation by LPS. 8 The hypothesis of a general immunosuppression is, however, not completely compatible with the observation that patients treated by PCE are not functionally immunodepressed (they do not have any higher risk to develop infections or cancers). Moreover, experimental studies have shown the development of active specific rather than suppressive nonspecific immune response. 9, 10 However, such cytokines could contribute to the activation or the generation of regulatory T cells induced by dendritic cells (DC). 11, 12 Focus on DC is of particular interest, because DC are potential candidates in the control of the GVHD. 13 Indeed, DC play a central role in the initiation of immune response. In humans, there is a heterogeneous population of cells, and at least two distinct circulating subsets can be identified: myeloid DC (MDC) and plasmacytoid DC (PDC).
14,15 Immature CD11c þ MDC are efficient to capture and process antigen, and after maturation, they can produce IL12 and polarize naive T cells into IFN-g-producing Th1 cells; however, depending upon the context of their encounter with the antigen, they can also prime a Th2 response. PDC are characterized by a plasma-like morphology, the coexpression of CD4 and HLA-DR molecule in the absence of lineage markers (CD3, CD19, CD13, CD11c), and a high-level expression of the IL-3Ra chain (CD123), CD45RA, BDCA-2, and BDCA-4. In response to virus, PDC secrete high levels of IFN-a and induce a Th1 polarization of T-helper cells. Whether this polarization is dependent on either IFN-a or IL-12 is still a controversial subject. In the context of an activation with CD40L or with IL-3, PDC have been shown to rather prime naive T cells towards a Th2 pathway, 16, 17 in an IL-4-independent way, and to generate IL-10-producing CD8 T-regulatory cells.
are able to acquire, process, and present viral antigens to induce the proliferation and differentiation of antiviral CD8 þ and CD4 þ T cells. 19 In allogeneic hematopoeitic cell transplantation, the role of DC in the control of the alloreactive conflict post-allograft still remains debated. Numerous studies try to define the importance of subset distribution (myeloid vs lymphoid) and origin of DC (donor or recipient) in this reaction. 13 In this context, it appears interesting to study the impact of ECP on the functionality of DC compartment in patients with GVHD.
Recently, to investigate the effects of ECP on chronic GVHD, Gorgun et al 20 examined DC subpopulations and helper T-cell differentiation during the treatment. The results presented are, however, rather confusing. Indeed, the authors claim that they uncovered a shift in the balance MDC/PDC. However, the authors defined MDC as CD80 þ CD123 low cells and PDC as CD83 þ CD86 þ cells, a definition in contradiction with the standard classification of DC. Indeed, MDC are Lin-DR þ CD11c þ CD123-circulating cells, whereas PDC are Lin-DR þ CD11c-CD123
high . The expression of CD80, CD83, and CD86 can be acquired by both subsets of DC during the process of maturation, and cannot identify exclusively MDC or PDC. Furthermore, the evaluation of DC phenotype and function is based on the characterization of cells derived from peripheral blood mononuclear cells after culture with GM-CSF þ IL4, followed by maturation with TNFa and PMA. Such a protocol is known to induce the differentiation of monocytes into mature MDC. 21 The phenotype of mature MDC (CD83 þ CD86 þ ) at the end of the culture is the reflection of this differentiation, and cannot demonstrate a shift from MDC to PDC, as the authors conclude. The experiments done are not suitable to evaluate the proportion of MDC or PDC, but only show that monocytes are still able to differentiate into mature MDC. Variations in the percentage of positive cells for the different markers could only be interpreted as an effect of ECP on this ex vivo maturation. Another possible effect of ECP described in this paper is the shift from a Th1 to a Th2 profile of circulating T cells. However, the data presented cannot be really interpreted. Indeed, due the absence of appropriate controls, the data do not allow the evaluation of cytokine secretion, since no convincing staining can be detected either for INFg, IL4 or IL10, and for CD4 or CD8. Altogether, since the authors do not provide any firm evidence demonstrating either a shift from MDC to PDC, or from Th1 to Th2 profile, the data presented by Gorgun et al cannot be considered as relevant to explain the immunological effect of ECP in the control of GHVD.
Even if it is sometimes difficult to perform experimental experiments with cells from patients after allogeneic hematopoietic cell transplantation, more appropriate studies must be realized to know whether DC could be involved in the control of GVHD after ECP. Experimental studies in mice suggested a possible development of a T-cell response capable of regulating pathogenic T cells. Such an immune response probably expands through the activation of DC, as they are the most powerful antigen-presenting cells in immune system. However, many questions remain unsolved, such as the consequence of the reinfusion of preapoptotic cells on antigen presentation by DC, the subset of DC involved, the nature of antigen recognized, the type of T-cell response induced (regulatory T cells ?), etc.
A better knowledge of the mechanisms of action of ECP is crucial for an improvement of this cell therapy, allowing to better define the pathologies where ECP could be efficient, the criteria of inclusion of the patients, and the rate and duration of the treatment protocol.
